ArticleMicrobial cell factories2026
The impact of evolutionary dynamics and expression plasmid stability on long-term heterologous protein production by yeast.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBaker's yeast, Saccharomyces cerevisiae, is a widely used industrial host organism for heterologous protein production. Ensuring stable, high-level production over extended production campaigns is important for low-cost manufacturing. However, maintaining consistent yields over multiple generations is challenging as strain productivity may decline over time. Understanding potential evolutionary mechanisms underlying such decline is therefore important for optimising yeast-based expression systems in continuous manufacturing.
resultsIn this study, diverse yeast libraries carrying high-copy-number whole-2-micron episomal expression plasmids producing a secreted SARS-CoV-2 spike protein fragment fused to mCherry were used to investigate fluorescence-based production stability during prolonged cultivation in yeast. We observed that while some strains maintained relatively stable mCherry fluorescence, most strains with high initial total fluorescence showed marked declines over 140 generations. Growth assays indicated that cultures with reduced mCherry fluorescence had a fitness advantage over high-fluorescence cultures. The decline was partly explained by phenotypic heterogeneity among genetically uniform cells; early-stage (10th generation) cultures contained distinct, non-fluorescent, low-fluorescence and high-fluorescence subpopulations (these subpopulation phenotypes were non-heritable), whereas evolved low-fluorescence cultures after 140 generations displayed loss of the high- and/or low-fluorescence subpopulations and reduced cell-to-cell heterogeneity. Despite this, the selected evolved low-fluorescence isolates had fluorescence restored to near-initial levels after being cured of their expression plasmids and retransformed with plasmids from early-stage, high-fluorescence cultures, indicating that, in the selected evolved low-fluorescence isolates analysed, plasmid-associated changes were sufficient to explain the stable reduction in mCherry fluorescence. Whole-plasmid sequencing of the episomal 2-micron expression plasmids isolated from low-fluorescence cultures at the 140th generation revealed mutations in key functional regions, including the methionine-regulated MET17 promoter driving SARS-CoV-2 protein expression, FRT recombination sites and the SARS-CoV-2 spike protein fragment coding sequence.
conclusionThe results support a model in which prolonged expression of a burdensome secreted recombinant protein can be associated with early non-genetic heterogeneity in intracellular mCherry fluorescence, growth advantages of low-fluorescence cells and evolution of plasmid variants that reduce expression. The extent of fluorescence decline varied among genetically diverse strains, with some remaining comparatively stable, highlighting the potential of exploiting yeast strain diversity to obtain production strains with improved long-term stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.